We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...

Jefferies has upgraded Crinetics (CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant. Read more here.

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to ...

Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in ...

Jefferies upgraded Crinetics Pharmaceuticals stock, moving the rating from Hold to Buy, while maintaining a price target of $55.00. The decision follows a notable decline in share price from $60 to ...

In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other biotech stocks with the biggest upside potential. While 2024 was a ...

Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), ...

Crinetics Pharmaceuticals (NASDAQ:CRNX), Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of ...